迷幻药对阿片类药物使用障碍的影响:临床前研究的范围审查
Alejandra Pulido-Saavedra1,2, Henrique Nunes Pereira Oliva1,2, Tiago Paiva Prudente3
1Department of Psychiatry, Yale University School of Medicine, 300 George Street, Suite 901, New Haven, CT, 06511, USA.
Cellular and molecular life sciences : CMLS
|January 20, 2025
概括
像伊博加因和胺这样的迷幻药在临床前研究中显示出它有望通过减少自我管理和戒断来治疗阿片类药物使用障碍 (OUD). 需要进一步的研究来探索更广泛的迷幻药选择及其OUD治疗的安全性.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 阿片类药物危机需要新的治疗方法,除了用于阿片类药物使用障碍 (OUD) 的现有药物之外.
- 初步证据表明,迷幻药可能为OUD提供治疗益处,但可靠的临床数据有限.
- 目前对OUD的治疗方法存在局限性,这促使人们寻找创新的治疗策略.
研究的目的:
- 系统地审查关于阿片类药物使用障碍 (OUD) 的迷幻药物的临床前体内研究.
- 在OUD治疗中弥合心理药物的临床前发现和潜在的临床应用之间的差距.
- 确定有前途的迷幻化合物和OUD治疗未来研究领域.
主要方法:
- 根据PRISMA-ScR指南,在主要数据库 (MEDLINE,Embase,Scopus,Web of Science) 进行了系统的文献搜索.
- 包括动物模型中的幻觉药物和阿片类药物的临床前体内研究,但不包括疼痛研究和不受控制的试验.
- 分析了40项研究,调查了古典和非古典迷幻药对阿片类药物自我管理,戒断和有条件的地方偏好的影响.
主要成果:
- 大多数研究表明,18-甲基冠利丁 (18-MC),伊波加因,诺里波加因和胺可降低阿片类药物自给和戒断症状.
- 七项研究报告说,对于某些迷幻药物,比对照组没有显著的改善,包括DOM,ibogaine,18-MC和ketamine.
- 方法质量评估显示,大多数研究的质量不清楚,临床前研究大力支持伊博加衍生物,这些衍生物可能带来心血管风险.
结论:
- 临床前证据支持进一步的翻译性研究,调查迷幻药作为阿片类药物使用障碍 (OUD) 的创新治疗方法.
- 未来的临床研究应该扩大范围超越iboga衍生品,包括其他迷幻药.
- 需要进一步研究OUD的幻化药物的作用机制,安全性,最佳剂量和施用频率.
相关概念视频
Analgesia and Pain Management
478
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
478
Opioid Analgesics: Synthetic and Semisynthetic Opioids
213
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
213
Opioid Analgesics: Morphine and Other Natural Cogeners
172
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
172
Drug Abuse and Addiction: Pharmacological Phenomena
433
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
433
CNS Stimulants: Psychedelic Agents
123
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
123
Opioid Receptors: Overview
481
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
481


